Evaluation of the Sporadic Anti-Alzheimer's Activity of Purpurin Using In Silico, In Vitro, and In Vivo Approaches
- PMID: 40210836
- DOI: 10.1007/s12035-025-04910-9
Evaluation of the Sporadic Anti-Alzheimer's Activity of Purpurin Using In Silico, In Vitro, and In Vivo Approaches
Abstract
Purpurin, a naturally occurring compound found in certain plants, has demonstrated promising neuroprotective effects in the context of Alzheimer's disease (AD). This study investigated the efficacy of purpurin in mitigating neurodegenerative changes induced by streptozotocin (3 mg/kg ICV) and amyloid beta (20 μM) in murine models. Neuroprotective effects were assessed through in vitro and in vivo experiments complemented by in silico simulation studies. SH-SY5Y cell viability, behavioral, biochemical, and histopathological studies were also conducted. The results revealed that purpurin interacts with acetylcholinesterase (AChE) and amyloid-beta (Aβ), exhibiting glide scores of - 10.72 and - 3.05 kcal/mol, respectively. Purpurin (8 μM) significantly alleviated Aβ-induced cellular damage by decreasing malondialdehyde production and enhancing superoxide dismutase and Thio barbituric acid reactive substances levels in a dose-dependent manner. Intraperitoneal administration of purpurin at 50 mg/kg significantly improved both long-term and short-term memory and enhanced social interactions. These benefits were linked to the reductions in AChE activity and oxidative and inflammatory marker levels triggered by streptozotocin. Neuroprotective effects were also supported by restoring neuronal DNA content in the hippocampus, cerebellum and prefrontal cortex. Histological findings further corroborated the reduction in neurodegenerative marker levels. In silico simulations supported these findings by indicating that purpurin primarily binds to the Trp 286 and Tyr 341 residues of AChE, inhibiting its catalytic activity at the peripheral anionic site. In conclusion, the neuroprotective activity of purpurin in AD models is attributed to its inhibitory effects on AChE, coupled with reductions in inflammation and oxidative stress and the restoration of neuronal DNA integrity in critical brain regions.
Keywords: Alzheimer’s disease; Amyloid beta; Memory; Purpurin; Social behavior; Streptozotocin.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethics Approval: All the animal experiments (Ref. no. BV/3533/2017–18) were preapproved by the Institutional Animal Ethical Committee of Banasthali Vidyapith, and the animal experiments were performed according to the CPCSEA guidelines. Consent to Participate: Not applicable. Consent for Publication: Not applicable. Competing Interests: The authors declare no competing interests.
Similar articles
-
Design, synthesis, and biological evaluation of caffeic acid-based novel multifunctional molecules for the management of Alzheimer's disease.Eur J Med Chem. 2025 Oct 15;296:117831. doi: 10.1016/j.ejmech.2025.117831. Epub 2025 Jun 10. Eur J Med Chem. 2025. PMID: 40578253
-
Neuroprotective Effects of Sulforaphane in a rat model of Alzheimer's Disease induced by Aβ (1-42) peptides.Neurochem Int. 2024 Oct;179:105839. doi: 10.1016/j.neuint.2024.105839. Epub 2024 Aug 21. Neurochem Int. 2024. PMID: 39173832
-
Neuroprotective Effects of a Benzofuran-Containing Selenium in a Mouse Alzheimer's Disease Model: Molecular, Biochemical, and Behavioral Analyses.ACS Chem Neurosci. 2025 Jul 2;16(13):2420-2434. doi: 10.1021/acschemneuro.5c00139. Epub 2025 Jun 16. ACS Chem Neurosci. 2025. PMID: 40523837 Free PMC article.
-
Unveiling the Protective Roles of Melatonin on Glial Cells in the Battle Against Alzheimer's Disease-Insights from In Vivo and In Vitro Studies.Mol Neurobiol. 2025 Aug;62(8):10414-10426. doi: 10.1007/s12035-025-04904-7. Epub 2025 Apr 10. Mol Neurobiol. 2025. PMID: 40208552 Review.
-
Experimental Evidence of Caffeic Acid's Neuroprotective Activity in Alzheimer's Disease: In Vitro, In Vivo, and Delivery-Based Insights.Medicina (Kaunas). 2025 Aug 8;61(8):1428. doi: 10.3390/medicina61081428. Medicina (Kaunas). 2025. PMID: 40870473 Free PMC article.
Cited by
-
Apolipoprotein-decorated drug loaded liposomes mitigating copper intoxication: an in vitro and in vivo evidence-based study intervening Wilson disease.Naunyn Schmiedebergs Arch Pharmacol. 2025 May 14. doi: 10.1007/s00210-025-04226-4. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40366400
References
-
- Alzheimer’s Association Annual Report. Vol 13. Chicago; 2015. http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emexb&a... . Accessed on 28 July 2024
-
- Alzheimer association; 10 Early Signs and Symptoms of Alzheimer’s & Dementia. https://www.alz.org/alzheimers-dementia/10_signs Accessed on 24 July 2024
-
- Santana I, Farinha F, Freitas S et al (2015) The epidemiology of dementia and Alzheimer disease in Portugal: estimations of prevalence and treatment-costs. Acta Med Port 28:182–188. https://doi.org/10.20344/amp.6025 - DOI - PubMed
-
- Anand R, Gill KD, Mahdi AA (2014) Therapeutics of Alzheimer’s disease: past, present and future. Neuropharmacology 76:27–50. https://doi.org/10.1016/j.neuropharm.2013.07.004 - DOI - PubMed
-
- Vaz M, Silva V, Monteiro C et al (2022) Role of aducanumab in the treatment of alzheimer’s disease: challenges and opportunities. CIA 17:797–810. https://doi.org/10.2147/CIA.S325026 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical